Venus Remedies saw its shares jumped 10% after securing the renewal of its European Good Manufacturing Practices (EU GMP) certification from Infarmed, Portugal’s National Authority of Medicines and Health Products. This achievement highlights the company’s steadfast commitment to delivering high-quality pharmaceutical products to the European market.
Venus Remedies shares opened at ₹308.95, with a high of ₹332.40 and a low of ₹303.55 during the trading session. Over the past year, the stock reached a 52-week high of ₹427.90 and a low of ₹281.10, reflecting volatility. As of 9:25 AM, the shares were trading 10.63% higher at Rs 326.75.
The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and oncology formulations, validating Venus Remedies’ adherence to stringent quality and safety standards. With over 15 years of strong market presence in Europe, Venus Remedies is a recognized leader, particularly as a top exporter of Meropenem outside India, holding multiple marketing authorizations across the region.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
